Literature DB >> 27330791

Complete diagnostics and clinical approach for a female patient with unusual glioblastoma: A case study.

Filip Samal1, Libor Stanek2, Michal Filip1, Pavel Haninec1, Ales Vícha3, Zdenek Musil4, Petra Tesarova5, Lubos Petruzelka5, Drahomira Springer6, Milena Kralickova7, Milada Kohoutova8, Tomas Zima6.   

Abstract

The present study reports a case of a 44-year-old female patient with a large frontal lobe tumor who underwent surgery using a modern navigation system SonoWand that combines the advantages of a non-frame navigation system with intraoperative real-time ultrasound imaging. The right frontal lobe tumor consisted of two morphologically different sections. A diffuse astrocytoma grade II and a glioblastoma grade IV were identified. These tumors were relatively substantially separated. A 17 p deletion, including TP53, was detected in a diffuse astrocytoma but not in a glioblastoma. EGFR and MDM2 amplifications were detected only in a glioblastoma. Detection of these amplifications is typical for primary glioblastomas. These findings support our assumption of two independent tumors. The KRAS, BRAF and EGFR gene mutations were also detected in a glioblastoma. Such an accumulation of molecular mutations is rare in one tumor. Following oncological treatment the patient was cared for in the oncological center and survived for 15 months after the surgery without any signs of a disease. This is an unusual case, and to the best of our knowledge, is not frequently published in literature.

Entities:  

Keywords:  RAS mutation; duplicate tumor; glioblastoma multiforme; low-grade glioma; sononavigation

Year:  2016        PMID: 27330791      PMCID: PMC4906621          DOI: 10.3892/mco.2016.891

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  14 in total

1.  The clinicopathologic values of the molecules associated with the main pathogenesis of the glioblastoma.

Authors:  Bomi Kim; Jae Kyung Myung; Ja Hee Seo; Chul-Kee Park; Sun Ha Paek; Dong Gyu Kim; Hee-Won Jung; Sung-Hye Park
Journal:  J Neurol Sci       Date:  2010-05-02       Impact factor: 3.181

2.  Vascular endothelial growth factor (VEGF) in astrocytic gliomas--a prognostic factor?

Authors:  R D Oehring; M Miletic; M M Valter; T Pietsch; J Neumann; R Fimmers; U Schlegel
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

3.  Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas.

Authors:  Christiane B Knobbe; Julia Reifenberger; Guido Reifenberger
Journal:  Acta Neuropathol       Date:  2004-10-28       Impact factor: 17.088

4.  Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration.

Authors:  Yolanda Ruano; Teresa Ribalta; Angel Rodríguez de Lope; Yolanda Campos-Martín; Concepción Fiaño; Elisa Pérez-Magán; José-Luis Hernández-Moneo; Manuela Mollejo; Bárbara Meléndez
Journal:  Am J Clin Pathol       Date:  2009-02       Impact factor: 2.493

Review 5.  MDM2 and MDM4: p53 regulators as targets in anticancer therapy.

Authors:  Franck Toledo; Geoffrey M Wahl
Journal:  Int J Biochem Cell Biol       Date:  2007-04-08       Impact factor: 5.085

Review 6.  Genetic alterations and signaling pathways in the evolution of gliomas.

Authors:  Hiroko Ohgaki; Paul Kleihues
Journal:  Cancer Sci       Date:  2009-08-06       Impact factor: 6.716

7.  Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control.

Authors:  C Deng; P Zhang; J W Harper; S J Elledge; P Leder
Journal:  Cell       Date:  1995-08-25       Impact factor: 41.582

8.  A comprehensive pathway map of epidermal growth factor receptor signaling.

Authors:  Kanae Oda; Yukiko Matsuoka; Akira Funahashi; Hiroaki Kitano
Journal:  Mol Syst Biol       Date:  2005-05-25       Impact factor: 11.429

9.  Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response.

Authors:  Julie Sesen; Perrine Dahan; Sarah J Scotland; Estelle Saland; Van-Thi Dang; Anthony Lemarié; Betty M Tyler; Henry Brem; Christine Toulas; Elizabeth Cohen-Jonathan Moyal; Jean-Emmanuel Sarry; Nicolas Skuli
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

10.  Expression of bFGF and VEGF in brain astrocytoma.

Authors:  J W Shim; Y C Koh; H K Ahn; Y E Park; D Y Hwang; J G Chi
Journal:  J Korean Med Sci       Date:  1996-04       Impact factor: 2.153

View more
  1 in total

1.  Infrequent RAS mutation is not associated with specific histological phenotype in gliomas.

Authors:  Yasuhide Makino; Yoshiki Arakawa; Ema Yoshioka; Tomoko Shofuda; Sachiko Minamiguchi; Takeshi Kawauchi; Masahiro Tanji; Daisuke Kanematsu; Masahiro Nonaka; Yoshiko Okita; Yoshinori Kodama; Masayuki Mano; Takanori Hirose; Yohei Mineharu; Susumu Miyamoto; Yonehiro Kanemura
Journal:  BMC Cancer       Date:  2021-09-15       Impact factor: 4.638

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.